Retatrutide | GLP-1 GIP GCG Peptides | 99%+ Purity | 10mg 15mg 20mg 30mg Vials | Lyophilized Powder

  Product Detail  

Retatrutide is a new type of multi-target peptide drug developed by Eli Lilly and Company of the United States, it is a triple receptor agonist of GLP-1R/GIPR/GCGR. Its core mechanism is to regulate the metabolic process by activating glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) receptors at the same time, and is used for the treatment of obesity and type 2 diabetes.

Mechanism of Action and Molecular Structure of Retatrutide:

1)Triple Agonist Design
- GLP-1 receptor: Retatrutide delays gastric emptying, suppress appetite, and promote insulin secretion.
- GIP receptor: Retatrutide enhances insulin sensitivity and regulate central satiety signals.
- Glucagon receptor (GCGR): Retatrutide activates liver energy metabolism, promote lipolysis and lycogenolysis, and increase basal metabolic rate.
The triple synergistic effect increases energy consumption while reducing energy intake, significantly improving weight loss effects.

2) Structural Optimization
- Based on the GIP skeleton modification, non-natural amino acids (such as α-methylleucine at position 13) are introduced to enhance receptor affinity.
- The half-life is extended to 7 days through fatty acid side chain modification。

These products are APIs (Active Pharmaceutical Ingredient) and not a finished drug. 

It is intended strictly for research and laboratory use only.

Buyers are required to fully comply with all applicable laws and regulations regarding the handling and use of this material.

  Q&A